Hosted on MSN

FDA Approves Risperidone Extended-Release Injectable Option for Bipolar 1 Disorder

The first under-the-skin, long-acting risperidone injection offers a new maintenance option for adults with bipolar 1 disorder. For anyone managing bipolar 1 disorder, staying consistent with daily ...
Seeking Alpha

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA ...
Medscape

Long-Acting Risperidone Injection

The potentially devastating consequences of a relapse in patients with schizophrenia and the substantial risk of relapse associated with even partial compliance with therapy have made compliance a ...
Business Wire

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the ...

The RISE study 7 was a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of risperidone extended-release injectable suspension for subcutaneous use as a ...